HK1208805A1 - 用於治療癌症的β-水解酶抑制劑 - Google Patents

用於治療癌症的β-水解酶抑制劑 Download PDF

Info

Publication number
HK1208805A1
HK1208805A1 HK15109523.0A HK15109523A HK1208805A1 HK 1208805 A1 HK1208805 A1 HK 1208805A1 HK 15109523 A HK15109523 A HK 15109523A HK 1208805 A1 HK1208805 A1 HK 1208805A1
Authority
HK
Hong Kong
Prior art keywords
methyl
hydroxy
acetoxy
fluorophenyl
furanon
Prior art date
Application number
HK15109523.0A
Other languages
English (en)
Chinese (zh)
Inventor
.萬茲
J.R.万兹
.德拉蒙特
S.德拉蒙特
.相原
A.相原
.奧爾森
M.J.奥尔森
.托馬斯
J-M.托马斯
Original Assignee
罗得岛医院
美国中西部大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 罗得岛医院, 美国中西部大学 filed Critical 罗得岛医院
Publication of HK1208805A1 publication Critical patent/HK1208805A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15109523.0A 2012-09-21 2013-09-20 用於治療癌症的β-水解酶抑制劑 HK1208805A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US61/704,014 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer

Publications (1)

Publication Number Publication Date
HK1208805A1 true HK1208805A1 (zh) 2016-03-18

Family

ID=50342080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109523.0A HK1208805A1 (zh) 2012-09-21 2013-09-20 用於治療癌症的β-水解酶抑制劑

Country Status (10)

Country Link
US (8) US9771356B2 (enExample)
EP (2) EP3345596B1 (enExample)
JP (1) JP6469009B2 (enExample)
KR (1) KR102137180B1 (enExample)
CN (2) CN110818660B (enExample)
AU (1) AU2013317791B2 (enExample)
CA (1) CA2885762C (enExample)
ES (2) ES2865412T3 (enExample)
HK (1) HK1208805A1 (enExample)
WO (2) WO2014047447A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂
WO2019012159A1 (en) * 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
US10961320B2 (en) 2018-06-18 2021-03-30 Midwestern University Monoclonal antibodies targeting epitopes of ASPH
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用
EP3923922A4 (en) 2019-02-15 2022-03-30 Midwestern University Isotopically-stabilized tetronimide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
DD39717A (enExample) *
WO1987000729A1 (en) * 1985-08-02 1987-02-12 Chevron Research Company Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans
US5314913A (en) * 1992-12-08 1994-05-24 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp 4‐アシルオキシフラノン誘導体又はその塩及びその製造方法
US5698585A (en) * 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ATE244232T1 (de) * 1997-03-14 2003-07-15 Merck Frosst Canada Inc (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
WO2003018575A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
AU2002950862A0 (en) * 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
DE60330587D1 (de) * 2002-10-16 2010-01-28 Isis Innovation Screening-Methoden unter Verwendung eines Strukturmodells von FIH
WO2005070916A1 (en) * 2004-01-09 2005-08-04 Eli Lilly And Company Thiophene and furan compounds
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
EP2576532B1 (en) * 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂

Also Published As

Publication number Publication date
ES2865412T3 (es) 2021-10-15
CA2885762C (en) 2022-05-03
ES2660822T3 (es) 2018-03-26
CA2885762A1 (en) 2014-03-27
US10710995B2 (en) 2020-07-14
US10787445B2 (en) 2020-09-29
US20150210677A1 (en) 2015-07-30
JP6469009B2 (ja) 2019-02-13
US20190002453A1 (en) 2019-01-03
WO2014047519A2 (en) 2014-03-27
US10351555B2 (en) 2019-07-16
US20220251076A1 (en) 2022-08-11
US20210032233A1 (en) 2021-02-04
KR20150079616A (ko) 2015-07-08
US9771356B2 (en) 2017-09-26
WO2014047447A2 (en) 2014-03-27
CN110818660A (zh) 2020-02-21
AU2013317791B2 (en) 2018-05-10
EP3345596B1 (en) 2021-01-20
EP2897607A2 (en) 2015-07-29
US20190300519A1 (en) 2019-10-03
US20180009798A1 (en) 2018-01-11
US10106532B2 (en) 2018-10-23
US20180237427A1 (en) 2018-08-23
EP3345596A3 (en) 2018-10-03
WO2014047519A3 (en) 2014-05-30
EP3345596A2 (en) 2018-07-11
WO2014047447A3 (en) 2015-07-30
AU2013317791A1 (en) 2015-05-07
KR102137180B1 (ko) 2020-07-24
EP2897607A4 (en) 2016-10-05
CN110818660B (zh) 2023-09-12
JP2015531351A (ja) 2015-11-02
US20200361925A1 (en) 2020-11-19
EP2897607B1 (en) 2017-11-22
CN104902889A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
CN102424681B (zh) 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
US20220251076A1 (en) Inhibitors of Beta-Hydoxylase for Treatment of Cancer
JPWO2015083833A1 (ja) 新規キナゾリン誘導体
WO2016034634A1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak
JP2023523036A (ja) Lox酵素阻害方法及び組成物
US11897857B2 (en) Isotopically-stabilized tetronimide compounds
WO2019196780A1 (zh) 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途